Biodesix, Inc. (NASDAQ:BDSX) Shares Bought by Perkins Capital Management Inc.

Perkins Capital Management Inc. lifted its stake in shares of Biodesix, Inc. (NASDAQ:BDSX) by 74.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 724,782 shares of the company’s stock after purchasing an additional 310,000 shares during the quarter. Biodesix comprises 1.2% of Perkins Capital Management Inc.’s portfolio, making the stock its 27th largest position. Perkins Capital Management Inc.’s holdings in Biodesix were worth $1,290,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in BDSX. Opaleye Management Inc. grew its stake in Biodesix by 7.7% during the 1st quarter. Opaleye Management Inc. now owns 534,657 shares of the company’s stock worth $765,000 after buying an additional 38,157 shares during the last quarter. CVI Holdings LLC bought a new stake in Biodesix in the second quarter valued at $59,000. Farallon Capital Management LLC acquired a new position in shares of Biodesix during the second quarter valued at $2,874,000. Perceptive Advisors LLC bought a new position in shares of Biodesix during the second quarter worth about $3,326,000. Finally, AIGH Capital Management LLC increased its holdings in shares of Biodesix by 74.0% in the 2nd quarter. AIGH Capital Management LLC now owns 5,779,812 shares of the company’s stock worth $8,843,000 after acquiring an additional 2,458,727 shares during the period. 20.96% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

BDSX has been the subject of a number of analyst reports. Craig Hallum initiated coverage on shares of Biodesix in a research note on Friday, July 26th. They set a “buy” rating and a $3.00 target price for the company. Scotiabank began coverage on Biodesix in a report on Monday, September 16th. They set a “sector outperform” rating and a $3.00 price target on the stock. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Biodesix presently has an average rating of “Buy” and an average price target of $3.06.

Biodesix Stock Performance

Shares of BDSX opened at $1.33 on Thursday. The firm has a market capitalization of $193.47 million, a PE ratio of -3.41 and a beta of 1.22. The company has a quick ratio of 3.28, a current ratio of 3.28 and a debt-to-equity ratio of 0.99. The firm has a 50-day moving average price of $1.70 and a 200 day moving average price of $1.61. Biodesix, Inc. has a 52-week low of $1.15 and a 52-week high of $2.21.

Biodesix (NASDAQ:BDSX) last posted its quarterly earnings data on Friday, November 1st. The company reported ($0.07) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.07). Biodesix had a negative net margin of 66.84% and a negative return on equity of 369.89%. The business had revenue of $18.15 million during the quarter, compared to analysts’ expectations of $18.45 million. During the same period last year, the firm posted ($0.12) earnings per share. On average, sell-side analysts anticipate that Biodesix, Inc. will post -0.36 earnings per share for the current fiscal year.

Insider Buying and Selling at Biodesix

In other news, Chairman John Patience acquired 75,000 shares of the business’s stock in a transaction dated Tuesday, November 5th. The stock was acquired at an average price of $1.38 per share, for a total transaction of $103,500.00. Following the completion of the acquisition, the chairman now directly owns 2,153,298 shares in the company, valued at $2,971,551.24. This represents a 0.00 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. In other Biodesix news, Chairman John Patience acquired 75,000 shares of the stock in a transaction dated Tuesday, November 5th. The shares were bought at an average price of $1.38 per share, with a total value of $103,500.00. Following the purchase, the chairman now directly owns 2,153,298 shares of the company’s stock, valued at approximately $2,971,551.24. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Matthew Strobeck bought 40,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 5th. The stock was acquired at an average price of $1.40 per share, for a total transaction of $56,000.00. Following the completion of the acquisition, the director now directly owns 2,606,879 shares in the company, valued at approximately $3,649,630.60. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 5,359 shares of company stock valued at $8,533. 69.20% of the stock is owned by corporate insiders.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.